Highly dispersible granulate for the preparation of formulations of high dosage active substances and procedure for obtaining high dosage active substances thereof

Inactive Publication Date: 2013-05-02
SMART PHARMA SOLUTIONS
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0002]The object of the invention is to obtain high-concentration tablets, with a high disaggregation rate of the active princi

Problems solved by technology

Due to its fatty character and low melting point, it is difficult to manufacture the tablets, and to release it once the tablets have been prepared.
On the other hand, when the product melts, the particle size

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Highly dispersible granulate for the preparation of formulations of high dosage active substances and procedure for obtaining high dosage active substances thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020]The invention represents a technological advance in this field, since it improves the release time of ibuprofen, with the beneficial effects that this entails.

[0021]More specifically, the tablet proposed by the invention focuses its characteristics on the fact that it incorporates two components, which participate therein with the following proportions:[0022]Ibuprofen between—96% and 97%[0023]Disaggregating agent—between 4% and 3%

[0024]As a disaggregating agent, one or a mixture of the following products may be used:[0025]Croscarmellose[0026]Crospovidone[0027]Sodium carboxymethyl starch (Primogel)

[0028]The procedure for obtaining and manufacturing the aforementioned tablet involves subjecting the mixture of the two aforementioned products to a dry compaction phase, preferably by means of a refrigerated roller compactor, in order to subsequently transform said compacted product into a granulated product, with the aid of a rotary or rolling granulator.

[0029]This granulated product

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

By mixing ibuprofen and a disaggregating agent, the invention involves using these components in a proportion ranging between 96% and 97% by weight for ibuprofen, and between 3% and 4% for the disaggregating agent, which may be Sodium croscarmellose, Crospovidone or Sodium carboxymethyl starch, as well as a mixture thereof. Following the mixing of the raw materials, the mixture is subjected to compaction, granulation and subsequent compression, in order to finally give the tablet a coating; this leads to a significant cost reduction and a significant reduction in the active principle release time, such that the pharmacological action is very fast in time.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner SMART PHARMA SOLUTIONS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products